Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session

6MO - Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors

Date

07 Mar 2022

Session

Mini Oral session

Presenters

Wael Jdey

Citation

Annals of Oncology (2022) 33 (suppl_1): S3-S6. 10.1016/annonc/annonc842

Authors

W. Jdey1, V. Trochon-joseph2, C. Doizelet2, V. Hayes2, A. Cohendet1, M. Lienafa2, C. Zandanel1, O. De Beaumont1, J. Miara1

Author affiliations

  • 1 Onxeo, Paris/FR
  • 2 Onxeo, 75015 - Paris/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract 6MO

Background

PARP inhibitors (PARPi) have shown significant benefits in cancer patients with deficient homologous recombination repair (HRD; induced by BRCA mutations for example). However, they show no or very limited efficacy in tumors with active or proficient homologous recombination repair (HRP). In the current study, we propose a novel therapeutic strategy, based on drug combination to achieve synthetic lethality independently of the tumor genetics.

Methods

AsiDNATM is a double-strand DNA molecule that mimics endogenous DNA breaks to interfere with the DNA damage (DD) response. This decoy agonist molecule induces a false DD signaling through DNA-PK over-activation, and thus hijacks several DNA repair proteins from sites of real DD. We analyzed the effects of AsiDNA treatment on double strand break repair activities through homologous recombination and assessed the efficacy of the combination with PARPi (Olaparib and Talazoparib) in HRP tumor models.

Results

The AsiDNA-induced false damage signaling abrogated the HR repair through a “bluring” effect which limited the efficient recruitment of HR proteins (BRCA1, RAD51) to sites of PARPi-induced double-strand DNA breaks. The combined treatment induced a drug-driven synthetic lethality which was specific to tumor cells and is not observed in non-tumor cells predicting a good safety of the association. The AsiDNA-induced functional HRD was confirmed in different tumor models (breast, ovarian and prostate cancer cells) and is driven for at least one to two weeks after AsiDNA treatment, paving the way for a more appropriate patient-friendly treatment schedule. This concept was also validated in patient biopsies from DRIIV-1a clinical trial, where AsiDNA-treated tumors for three weeks showed clear tendency to switch from HRP to HRD. In addition to primary HRP tumors intrinsically resistant to PARPi, AsiDNA also sensitized de novo HRP tumors, that evolved from HRD to HRP under PARPi treatment pressure, through the restoration of the HR pathway.

Conclusions

These results point to the therapeutic opportunity of combining AsiDNA and PARPi in HRP tumors to overcome intrinsic or acquired resistance in clinical situation.

Legal entity responsible for the study

The authors.

Funding

Onxeo.

Disclosure

W. Jdey, V. Trochon-Joseph, C. Doizelet, V. Hayes, A. Cohendet, M. Lienafa, C. Zandanel, O. De Beaumont: Financial Interests, Institutional, Full or part-time Employment: Onxeo. J. Miara: Financial Interests, Institutional, Member of the Board of Directors: Onxeo.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.